诺瓦瓦克斯医药(NVAX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVAX 诺瓦瓦克斯医药

休市中 03-14 16:00:00 EDT

7.99

-0.18

-2.20%

盘后7.98

-0.01-0.10%

19:59 EDT

最高8.52	最低7.96	成交量503.83万
今开8.30	昨收8.17	日振幅6.92%
总市值12.85亿	流通市值10.83亿	总股本1.61亿
成交额4,130万	换手率3.72%	流通股本1.36亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVAX","market":"US","secType":"STK","nameCN":"诺瓦瓦克斯医药","latestPrice":7.99,"timestamp":1741982400000,"preClose":8.17,"halted":0,"volume":5038272,"hourTrading":{"tag":"盘后","latestPrice":7.9817,"preClose":7.99,"latestTime":"19:59 EDT","volume":101115,"amount":808430.6032,"timestamp":1741996760814},"delay":0,"floatShares":135597834,"shares":160844197,"eps":-1.232006,"marketStatus":"休市中","change":-0.18,"latestTime":"03-14 16:00:00 EDT","open":8.3,"high":8.52,"low":7.955,"amount":41295516.28128,"amplitude":0.069155,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.232006,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1742198400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":8.17,"preHourTrading":{"tag":"盘前","latestPrice":8.27,"preClose":8.17,"latestTime":"09:28 EDT","volume":23434,"amount":193638.6571,"timestamp":1741958908043},"postHourTrading":{"tag":"盘后","latestPrice":7.9817,"preClose":7.99,"latestTime":"19:59 EDT","volume":101115,"amount":808430.6032,"timestamp":1741996760814},"volumeRatio":1.405027783251826,"impliedVol":1.1922,"impliedVolPercentile":0.692},"requestUrl":"/m/hq/s/NVAX/tweets","defaultTab":"tweets","newsList":[{"id":"2517943013","title":"诺瓦瓦克斯医药2024财年实现净利润-1.87亿美元，同比增加65.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517943013","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517943013?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363246,"startTime":"0","endTime":"0","summary":"3月8日，诺瓦瓦克斯医药公布财报，公告显示公司2024财年净利润为-1.87亿美元，同比增加65.69%；其中营业收入为6.82亿美元，同比减少30.69%，每股基本收益为-1.23美元。从资产负债表来看，诺瓦瓦克斯医药总负债22.27亿美元，其中短期债务17.10百万美元，资产负债比为0.72，流动比率为0.98。机构评级：截至2025年3月8日，当前有7家机构对诺瓦瓦克斯医药目标价做出预测，其中目标均价为16.43美元，其中最低目标价为9.00美元，最高目标价为25.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000146abed6640&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000146abed6640&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVAX"],"gpt_icon":0},{"id":"2517920878","title":"美股抗疫概念股集体上涨，Moderna涨近16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517920878","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517920878?lang=zh_cn&edition=full","pubTime":"2025-03-06 05:54","pubTimestamp":1741211660,"startTime":"0","endTime":"0","summary":"每经AI快讯，周三（3月5日），美股抗疫概念股集体上涨，Moderna涨近16%，吉利德科学涨0.61%，诺瓦瓦克斯医药涨超2%，BioNTech涨逾4%，阿斯利康涨0.92%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202503063337642255.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503063337642255.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","IE00BSNM7G36.USD","BK4547","LU1839511570.USD","LU2089984988.USD","BK4532","LU2087621335.USD","LU1066053197.SGD","IE00B19Z3581.USD","BK4583","LU0889565916.HKD","IE00BZ1G4Q59.USD","BK4566","BK4588","GILD","IE00BKVL7J92.USD","BK4585","LU1585245621.USD","LU0234570918.USD","LU1571399168.USD","LU1066051498.USD","BK4568","LU0289739699.SGD","BK4578","LU0320765992.SGD","NVAX","IE0002270589.USD","IE00B7SZLL34.SGD","LU2468319806.SGD","LU0058720904.USD","LU0109394709.USD","IE00B3T34201.USD","BK4550","IE00B19Z3B42.SGD","LU1430594728.SGD"],"gpt_icon":0},{"id":"2517948594","title":"诺瓦瓦克斯医药盘中异动 快速上涨5.34%报8.09美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517948594","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517948594?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:42","pubTimestamp":1741185753,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时42分，诺瓦瓦克斯医药股票出现异动，股价大幅拉升5.34%。截至发稿，该股报8.09美元/股，成交量30.5342万股，换手率0.19%，振幅3.91%。诺瓦瓦克斯医药股票所在的生物技术行业中，整体涨幅为0.70%。诺瓦瓦克斯医药公司简介：诺瓦瓦克斯医药公司是一家开发疫苗的生物技术公司。诺瓦瓦克斯与其全资拥有的瑞典子公司合作生产候选疫苗，以应对已知和新出现的疾病威胁。该公司认为，其疫苗技术有可能广泛应用于各种人类传染病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224233abe9b454&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224233abe9b454&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","BK4139","BK4585","BK4588","NVAX","BK4547"],"gpt_icon":0},{"id":"2516266817","title":"诺瓦瓦克斯医药盘中异动 下午盘快速跳水5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516266817","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516266817?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:12","pubTimestamp":1741032743,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时12分，诺瓦瓦克斯医药股票出现波动，股价快速下挫5.04%。截至发稿，该股报7.91美元/股，成交量441.937万股，换手率2.75%，振幅8.64%。诺瓦瓦克斯医药股票所在的生物技术行业中，整体涨幅为0.06%。诺瓦瓦克斯医药公司简介：诺瓦瓦克斯医药公司是一家开发疫苗的生物技术公司。诺瓦瓦克斯与其全资拥有的瑞典子公司合作生产候选疫苗，以应对已知和新出现的疾病威胁。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304041223989a5b82&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304041223989a5b82&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4568","BK4547","BK4585","BK4139","NVAX"],"gpt_icon":0},{"id":"1186632062","title":"异动解读 | 分析师发出\"买入\"评级推动诺瓦瓦克斯医药股价大涨14.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=1186632062","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186632062?lang=zh_cn&edition=full","pubTime":"2025-02-28 23:32","pubTimestamp":1740756771,"startTime":"0","endTime":"0","summary":"周五盘中,诺瓦瓦克斯医药(NVAX) 股价大涨14.73%,引发市场广泛关注。据报道,推动该股大涨的主因是一家分析师机构给予诺瓦瓦克斯医药\"买入\"评级,目标价高达19美元。\n截止当日收盘,诺瓦瓦克斯医药股价报收于7.765美元,较前一交易日大涨14.73%。全天振幅达3.82%,成交量28.26万股,换手率0.18%。\n诺瓦瓦克斯医药是一家致力于研发疫苗的生物技术公司,主要产品包括针对多种传染病的新型疫苗。资料显示,该公司在欧洲市场获得最大收入。分析师看好该股,认为公司有望从欧洲持续扩张业务,而此前\"买入\"评级显然给予市场极大信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVAX"],"gpt_icon":0},{"id":"2514375541","title":"美股异动 | 诺瓦瓦克斯医药(NVAX.US)涨近10% BTIG首予其“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2514375541","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514375541?lang=zh_cn&edition=full","pubTime":"2025-02-28 23:22","pubTimestamp":1740756151,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，诺瓦瓦克斯医药(NVAX.US)股价走高，截至发稿，该股涨近10%，报7.765美元。BTIG分析师Thomas Shrader首予诺瓦瓦克斯医药“买入”评级，目标价19美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1256524.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NVAX"],"gpt_icon":0},{"id":"2514378509","title":"诺瓦瓦克斯医药盘中异动 早盘快速拉升5.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514378509","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514378509?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:33","pubTimestamp":1740753180,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时33分，诺瓦瓦克斯医药股票出现波动，股价快速拉升5.38%。截至发稿，该股报7.44美元/股，成交量28.2614万股，换手率0.18%，振幅3.82%。诺瓦瓦克斯医药股票所在的生物技术行业中，整体涨幅为0.05%。诺瓦瓦克斯医药公司简介：诺瓦瓦克斯医药公司是一家开发疫苗的生物技术公司。诺瓦瓦克斯与其全资拥有的瑞典子公司合作生产候选疫苗，以应对已知和新出现的疾病威胁。该公司认为，其疫苗技术有可能广泛应用于各种人类传染病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223300a25801b1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223300a25801b1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","NVAX","BK4139","BK4547","BK4585","BK4588"],"gpt_icon":0},{"id":"2514538166","title":"美股异动｜诺瓦瓦克斯医药涨超9% Q4净亏损同比收窄 正加快研发新疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2514538166","media":"港股那点事","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514538166?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:26","pubTimestamp":1740669960,"startTime":"0","endTime":"0","summary":"格隆汇2月27日｜诺瓦瓦克斯医药(NVAX.US)涨超9%，报8美元。消息面上，诺瓦瓦克斯医药第四季度财报显示，净亏损为8100万美元，而去年同期净亏损为1.783亿美元，亏损收窄主要受益于新冠疫苗销售和管理费用的减少。期内新冠疫苗销售额仅为4980万美元，同比下降80.2%。面对市场需求疲软，公司正寄望于与Sanofi的合作带来的收入增长，同时加快推进新疫苗的研发。(格隆汇)               \n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2025-02-27/doc-inemxzxx7586100.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159646","BK4585","BK4139","NVAX","BK4588","BK4547","BK4568"],"gpt_icon":0},{"id":"2514389327","title":"诺瓦瓦克斯医药涨超4.5% Q4亏损有所收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2514389327","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514389327?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:47","pubTimestamp":1740667630,"startTime":"0","endTime":"0","summary":"周四，诺瓦瓦克斯医药(NVAX.US)股价走高，截至发稿，该股涨超4.5%，报7.61美元。在最新公布的第四季度财报显示，公司亏损有所收窄，主要受益于新冠疫苗销售和管理费用的减少。目前，该疫苗仍是诺瓦瓦克斯医药唯一在售的产品。截至12月31日的季度，其净亏损为8100万美元，而去年同期净亏损为1.783亿美元。诺瓦瓦克斯医药第四季度新冠疫苗销售额仅为4980万美元，同比大幅下降80.2%。面对市场需求疲软，公司正寄望于与Sanofi的合作带来的收入增长，同时加快推进新疫苗的研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227225506a2567fe3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227225506a2567fe3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4139","NVAX","BK4588","BK4547","BK4568"],"gpt_icon":0},{"id":"1123800958","title":"异动解读 | 诺瓦瓦克斯医药盘中大涨5.19%，亏损收窄业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1123800958","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123800958?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:43","pubTimestamp":1740667410,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药(NVAX)今日盘中股价大涨5.19%,引发市场关注。据报道,公司近期公布的2024年第四季度业绩超出了分析师预期,这是导致股价上涨的主要原因。\n\n具体来看,诺瓦瓦克斯医药第四季度每股亏损为0.51美元,与分析师的一致预期相符。与此同时,公司本季度销售额高达8831万美元,超出分析师预期的8438万美元。\n\n诺瓦瓦克斯医药的主打产品是新冠疫苗,但由于竞争加剧,该公司正在寻求产品线多元化。今年5月,诺瓦瓦克斯医药还与赛诺菲公司签署了12亿美元的协议,将其新冠疫苗在部分国家和地区的销售权移交给赛诺菲。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 诺瓦瓦克斯医药盘中大涨5.19%，亏损收窄业绩超预期","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVAX"],"gpt_icon":0},{"id":"2514859573","title":"美股异动 | 诺瓦瓦克斯医药(NVAX.US)涨超4.5% Q4亏损有所收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2514859573","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514859573?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:36","pubTimestamp":1740666987,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周四，诺瓦瓦克斯医药(NVAX.US)股价走高，截至发稿，该股涨超4.5%，报7.61美元。在最新公布的第四季度财报显示，公司亏损有所收窄，主要受益于新冠疫苗销售和管理费用的减少。目前，该疫苗仍是诺瓦瓦克斯医药唯一在售的产品。截至12月31日的季度，其净亏损为8100万美元，而去年同期净亏损为1.783亿美元。诺瓦瓦克斯医药第四季度新冠疫苗销售额仅为4980万美元，同比大幅下降80.2%。面对市场需求疲软，公司正寄望于与Sanofi的合作带来的收入增长，同时加快推进新疫苗的研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1255764.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4139","NVAX","BK4588","BK4547","BK4568"],"gpt_icon":0},{"id":"2514538363","title":"诺瓦瓦克斯医药盘中异动 早盘急速上涨5.60%报7.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514538363","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514538363?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:31","pubTimestamp":1740666668,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时31分，诺瓦瓦克斯医药股票出现异动，股价快速拉升5.60%。截至发稿，该股报7.73美元/股，成交量29.2256万股，换手率0.18%，振幅2.46%。诺瓦瓦克斯医药股票所在的生物技术行业中，整体涨幅为0.06%。诺瓦瓦克斯医药公司简介：诺瓦瓦克斯医药公司是一家开发疫苗的生物技术公司。诺瓦瓦克斯与其全资拥有的瑞典子公司合作生产候选疫苗，以应对已知和新出现的疾病威胁。该公司认为，其疫苗技术有可能广泛应用于各种人类传染病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223108abdf6e56&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223108abdf6e56&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4139","BK4568","NVAX","BK4547","BK4585"],"gpt_icon":0},{"id":"1178174443","title":"Novavax 2024年第四季度GAAP每股亏损0.51美元，与预期一致，销售额为8831万美元，超出预期的8438万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1178174443","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178174443?lang=zh_cn&edition=full","pubTime":"2025-02-27 21:12","pubTimestamp":1740661965,"startTime":"0","endTime":"0","summary":"Novavax报告季度每股亏损0.51美元，与分析师的共识预期一致。与去年同期每股亏损1.47美元相比，这一数字增加了65.31%。该公司报告季度销售额为8831万美元，超过了分析师共识预期的8438万美元，增幅为4.66%。以上内容来自Benzinga Earnings专栏，原文如下：Novavax  reported quarterly losses of $ per share which met the analyst consensus estimate. This is a 65.31 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $88.31 million which beat the analyst consensus estimate of $84.38 million by 4.66 percent.  This is a 69.69 percent decrease over ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVAX"],"gpt_icon":1},{"id":"1178211397","title":"Novavax 2024财年GAAP每股收益$(1.23)超过$(1.32)的预期，销售额$6.8216亿不及$6.8494亿预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1178211397","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178211397?lang=zh_cn&edition=full","pubTime":"2025-02-27 20:54","pubTimestamp":1740660869,"startTime":"0","endTime":"0","summary":"Novavax公布的季度亏损为每股$，高于分析师一致预期的$，超过预期6.82%。公司公布的季度销售额为$6.8216亿，低于分析师一致预期的$6.8494亿，低于预期0.41%。与去年同期$9.8371亿的销售额相比，下降了30.65%。以上内容来自Benzinga Earnings专栏，原文如下：Novavax  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 6.82 percent. This is a 77.26 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $682.16 million which missed the analyst consensus estimate of $684.94 million by 0.41 percent.  This ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Novavax 2024财年GAAP每股收益$(1.23)超过$(1.32)的预期，销售额$6.8216亿不及$6.8494亿预期","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVAX"],"gpt_icon":1},{"id":"2514480160","title":"Novavax(NVAX.US)：2024年Q4财报实现营收8831.1万美元，前值为2.913亿美元，预期值为8438万美元；每股收益为-0.52美元，前值为-1.47美元，预期值为-0.51美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514480160","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514480160?lang=zh_cn&edition=full","pubTime":"2025-02-27 20:51","pubTimestamp":1740660669,"startTime":"0","endTime":"0","summary":"Novavax(NVAX.US)：2024年Q4财报实现营收8831.1万美元，前值为2.913亿美元，预期值为8438万美元；每股收益为-0.52美元，前值为-1.47美元，预期值为-0.51美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27205148437303.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NVAX"],"gpt_icon":0},{"id":"2514701922","title":"美股抗疫概念股涨跌不一，诺瓦瓦克斯医药跌逾7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514701922","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514701922?lang=zh_cn&edition=full","pubTime":"2025-02-25 05:49","pubTimestamp":1740433797,"startTime":"0","endTime":"0","summary":"每经AI快讯，当地时间2月24日，美股抗疫概念股涨跌不一，Moderna跌超4%，吉利德科学涨近1%，诺瓦瓦克斯医药跌逾7%，BioNTech跌超2%，阿斯利康涨0.63%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202502253328109819.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502253328109819.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["NVAX","BK4568","BK4547","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"2513720440","title":"诺瓦瓦克斯医药盘中异动 早盘急速跳水5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513720440","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513720440?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:48","pubTimestamp":1740408485,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时48分，诺瓦瓦克斯医药股票出现波动，股价急速下跌5.07%。截至发稿，该股报7.59美元/股，成交量137.393万股，换手率0.86%，振幅4.26%。机构评级方面，在所有6家参与评级的机构中，50%的券商给予买入建议，33%的券商给予持有建议，17%的券商给予卖出建议。诺瓦瓦克斯医药股票所在的生物技术行业中，整体跌幅为0.02%。诺瓦瓦克斯与其全资拥有的瑞典子公司合作生产候选疫苗，以应对已知和新出现的疾病威胁。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224224805abdb1221&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224224805abdb1221&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVAX","BK4139","BK4547","BK4588","BK4585","BK4568"],"gpt_icon":0},{"id":"2513421584","title":"诺瓦瓦克斯医药盘中异动 股价大涨5.00%报8.32美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513421584","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513421584?lang=zh_cn&edition=full","pubTime":"2025-02-22 01:51","pubTimestamp":1740160267,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日01时51分，诺瓦瓦克斯医药股票出现波动，股价大幅拉升5.00%。截至发稿，该股报8.32美元/股，成交量170.47万股，换手率1.06%，振幅6.03%。机构评级方面，在所有6家参与评级的机构中，50%的券商给予买入建议，33%的券商给予持有建议，17%的券商给予卖出建议。诺瓦瓦克斯医药股票所在的生物技术行业中，整体涨幅为0.46%。诺瓦瓦克斯与其全资拥有的瑞典子公司合作生产候选疫苗，以应对已知和新出现的疾病威胁。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222015108962ba7f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222015108962ba7f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVAX","BK4588","BK4139","BK4568","BK4585","BK4547"],"gpt_icon":1},{"id":"2511503849","title":"美股抗疫概念股集体上涨，BioNTech涨近10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511503849","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511503849?lang=zh_cn&edition=full","pubTime":"2025-02-14 05:52","pubTimestamp":1739483555,"startTime":"0","endTime":"0","summary":"每经AI快讯，当地时间2月13日，美股抗疫概念股集体上涨，Moderna涨超4%，吉利德科学涨逾2%，诺瓦瓦克斯医药涨超4%，BioNTech涨近10%，阿斯利康涨0.03%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202502143318788770.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502143318788770.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0320765992.SGD","IE00B19Z3B42.SGD","IE0002270589.USD","IE00BKVL7J92.USD","LU2089984988.USD","BK4578","BK4583","LU1571399168.USD","GILD","LU0109394709.USD","BK4588","IE00BSNM7G36.USD","LU1839511570.USD","LU2087621335.USD","LU2468319806.SGD","LU1585245621.USD","IE00BZ1G4Q59.USD","LU0234570918.USD","BK4566","BK4139","IE00B3T34201.USD","BK4568","IE00B19Z3581.USD","LU0289739699.SGD","BK4547","LU1430594728.SGD","NVAX","IE00B7SZLL34.SGD","LU1066051498.USD","BK4532","LU0058720904.USD","LU0889565916.HKD","LU1066053197.SGD","BK4585","BK4550"],"gpt_icon":0},{"id":"2509708493","title":"美股抗疫概念股全线走低，Moderna跌约3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509708493","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509708493?lang=zh_cn&edition=full","pubTime":"2025-02-08 07:21","pubTimestamp":1738970485,"startTime":"0","endTime":"0","summary":"每经AI快讯，当地时间2月7日，美股抗疫概念股全线走低，Moderna跌约3%，吉利德科学跌超2%，诺瓦瓦克斯医药跌逾1%，BioNTech跌近2%，阿斯利康跌0.51%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202502083313781314.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502083313781314.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4578","IE00B7SZLL34.SGD","LU2089984988.USD","BK4566","LU1066053197.SGD","IE00BZ1G4Q59.USD","IE00B19Z3581.USD","BK4547","LU0289739699.SGD","LU1839511570.USD","GILD","LU0234570918.USD","LU2087621335.USD","BK4585","IE00BKVL7J92.USD","BK4583","BK4568","LU2468319806.SGD","LU1585245621.USD","LU0058720904.USD","LU1066051498.USD","LU0109394709.USD","NVAX","LU0320765992.SGD","BK4588","IE00BSNM7G36.USD","BK4532","LU1571399168.USD","IE0002270589.USD","IE00B19Z3B42.SGD","IE00B3T34201.USD","LU0889565916.HKD","BK4139","BK4550","LU1430594728.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novavax.com","stockEarnings":[{"period":"1week","weight":0.0381},{"period":"1month","weight":0.0111},{"period":"3month","weight":-0.1032},{"period":"6month","weight":-0.3997},{"period":"1year","weight":0.5562},{"period":"ytd","weight":0.0162}],"compareEarnings":[{"period":"1week","weight":-0.0372},{"period":"1month","weight":-0.089},{"period":"3month","weight":-0.0874},{"period":"6month","weight":-0.0188},{"period":"1year","weight":0.0687},{"period":"ytd","weight":-0.0591}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novavax, Inc.于1987年根据美国特拉华州法律注册成立，是一家临床阶段的生物制药公司，专注于重组纳米颗粒疫苗和佐剂的发现、开发和商业化。该公司的疫苗技术平台基于包括病毒样颗粒（VLP）和蛋白质纳米颗粒候选疫苗的专有重组纳米颗粒疫苗技术。该公司的候选疫苗是基因工程的三维纳米结构，其中包含了免疫学上重要的蛋白质。公司的疫苗产品管线针对多种传染病，候选药物目前处于呼吸道合胞病毒（RSV）、季节性流感、大流行性流感的临床开发阶段。此外，该公司在印度的合资公司CPL Biologics Private Limited（CPLB）正在积极开发多款候选疫苗，这些候选疫苗由诺瓦瓦克斯医药进行基因工程改造。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.101177},{"month":2,"riseRate":0.566667,"avgChangeRate":0.039349},{"month":3,"riseRate":0.266667,"avgChangeRate":-0.033862},{"month":4,"riseRate":0.448276,"avgChangeRate":0.007943},{"month":5,"riseRate":0.517241,"avgChangeRate":0.126888},{"month":6,"riseRate":0.517241,"avgChangeRate":0.09837},{"month":7,"riseRate":0.551724,"avgChangeRate":0.018176},{"month":8,"riseRate":0.517241,"avgChangeRate":0.037008},{"month":9,"riseRate":0.482759,"avgChangeRate":-0.043221},{"month":10,"riseRate":0.310345,"avgChangeRate":0.029378},{"month":11,"riseRate":0.344828,"avgChangeRate":0.002076},{"month":12,"riseRate":0.37931,"avgChangeRate":-0.038326}],"exchange":"NASDAQ","name":"诺瓦瓦克斯医药","nameEN":"Novavax"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.31.7","shortVersion":"4.31.7","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺瓦瓦克斯医药(NVAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺瓦瓦克斯医药(NVAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺瓦瓦克斯医药,NVAX,诺瓦瓦克斯医药股票,诺瓦瓦克斯医药股票老虎,诺瓦瓦克斯医药股票老虎国际,诺瓦瓦克斯医药行情,诺瓦瓦克斯医药股票行情,诺瓦瓦克斯医药股价,诺瓦瓦克斯医药股市,诺瓦瓦克斯医药股票价格,诺瓦瓦克斯医药股票交易,诺瓦瓦克斯医药股票购买,诺瓦瓦克斯医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺瓦瓦克斯医药(NVAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺瓦瓦克斯医药(NVAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}